The value of cell-free circulating tumour DNA profiling in advanced non-small cell lung cancer (NSCL...
The value of cell-free circulating tumour DNA profiling in advanced non-small cell lung cancer (NSCLC) management
About this item
Full title
Author / Creator
Publisher
England: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
Liquid biopsy (LB) has boosted a remarkable change in the management of cancer patients by contributing to tumour genomic profiling. Plasma circulating cell-free tumour DNA (ctDNA) is the most widely searched tumour-related element for clinical application. Specifically, for patients with lung cancer, LB has revealed valuable to detect the diversit...
Alternative Titles
Full title
The value of cell-free circulating tumour DNA profiling in advanced non-small cell lung cancer (NSCLC) management
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_ebca6d20dcbb423c9510de6aa5e7a3e5
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_ebca6d20dcbb423c9510de6aa5e7a3e5
Other Identifiers
ISSN
1475-2867
E-ISSN
1475-2867
DOI
10.1186/s12935-021-02382-0
